Synthesis of novel isothiazolopyridines and their in vitro evaluation against Mycobacterium and Propionibacterium acnes

Bioorganic and Medicinal Chemistry

Volumn 21, Issue 17, 2013, Pages 5282-5291

  Malinka, Wiesław ^a,e   Świa̧tek, Piotr ^a   Śliwińska, Małgorzata ^a   Szponar, Bogumiła ^b   Gamian, Andrzej ^a,b   Karczmarzyk, Zbigniew ^c   Fruziński, Andrzej ^d  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^c SIEDLCE UNIVERSITY OF NATURAL SCIENCES AND HUMANITIES   (Poland)

^d LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

^e Wroctaw College of Physiotherapy   (Poland)

Author keywords

Antibacterial activity; Antimycobacterial agents; Isothiazolopyridine; Synthesis

Indexed keywords

2 [2 (2 PHENOXYETHOXY)ETHYL] 4,6 DIMETHYLISOTHIAZOLO[5,4 B]PYRIDIN 3(2H) ONE; 2 [2 (N ETHYLCARBAMOILOXY)ETHYL] 4,6 DIMETHYLISOTIAZOLO[5,4 B]PYRIDIN 3(2H) ONE; 2 [2 (N N BUTHYLCARBAMOILOXY)ETHYL] 4,6 DIMETHYLISOTHIAZOLO[5,4 B]PYRIDIN 3(2H) ONE; 2 [2 (N PHENYLCARBAMOILOXY)ETHYL] 4,6 DIMETHYLIZOTHIAZOLO[5,4 B]PYRIDIN 3(2H) ONE; 2 [2 (N TERT BUTHYLCARBAMOILOXY)ETHYL] 4,6 DIMEHTYLISOTHIAZOLO[5,4 B]PYRIDIN 3(2H) ONE; 2 [2 [4 NITROPHENYL(PIPERAZINYL)]ETHYL] 4,6 DIMETHYLISOTHIAZOLO[5,4 B]PYRIDIN 3(2H) ONE; 2 [4 NITROPHENYL(PIPERAZINYL)METHYL] 4,6 DIMETHYLISOTHIAZOLO[5,4 B]PYRIDIN 3(2H) ONE; 3 [2 (2 PHENOXYETHYL)ETHOXY] 4,6 DIMETHYLISOTHIAZOLO[5,4 B]PYRIDINE; 3 [2 (N ETHYLCARBAMOILOXY)ETHOXY] 4,6 DIMETHYLISOTHIAZOLO[5,4 B]PYRIDINE; 3 [2 (N N BUTYLCARBAMOILOXY)ETHOXY] 4,6 DIMETHYLISOTHIAZOLO[5,4 B]PYRIDINE; 3 [2 (N PHENYLCARBAMOILOXY)ETHOXY] 4,6 DIMETHYLISOTHIAZOLO[5,4 B]PYRIDINE; 3 [2 (N TERT BUTHYLCARBAMOILOXY)ETHOXY] 4,6 DIMETHYLISOTHIAZOLO[5,4 B]PYRIDINE; ERYTHROMYCIN; ISONIAZID; ISOTHIAZOLOPYRIDINE DERIVATIVE; N,N BIS(4,6 DIMETHYL 3 OXO 2,3 DIHYDROISOTHIAZOLO[5,4 B]PYRIDIN 2 YLMETHYL) N 2 (3,4 DIMETHOXYPHENYLO)METHYLAMINE; N,N BIS(4,6 DIMETHYL 3 OXO 2,3 DIHYDROISOTHIAZOLO[5,4 B]PYRIDIN 2 YLMETHYL) N 2 CHLOROBENZYLAMINE; N,N BIS(4,6 DIMETHYL 3 OXO 2,3 DIHYDROISOTHIAZOLO[5,4 B]PYRIDIN 2 YLMETHYL) N 2 METHOXYBENZYLAMINE; N,N BIS(4,6 DIMETHYL 3 OXO 2,3 DIHYDROISOTHIAZOLO[5,4 B]PYRIDIN 2 YLMETHYL) N 2 PYRIDYLMETHYLAMINE; N,N BIS(4,6 DIMETHYL 3 OXO 2,3 DIHYDROISOTHIAZOLO[5,4 B]PYRIDIN 2 YLMETHYL) N 3,4 METHYLENODIOXYBENZYLAMINE; N,N BIS(4,6 DIMETHYL 3 OXO 2,3 DIHYDROISOTHIAZOLO[5,4 B]PYRIDIN 2 YLMETHYL) N 4 CHLOROBENZYLAMINE; N,N BIS(4,6 DIMETHYL 3 OXO 2,3 DIHYDROISOTHIAZOLO[5,4 B]PYRIDIN 2 YLMETHYL) N 4 METHOXYBENZYLAMINE; N,N BIS(4,6 DIMETHYL 3 OXO 2,3 DIHYDROISOTHIAZOLO[5,4 B]PYRIDIN 2 YLMETHYL) N BENZYLAMINE; PYRIDINE DERIVATIVE; RIFAMPICIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROPIONIBACTERIUM ACNES;

MYCOBACTERIUM; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM TUBERCULOSIS; PROPIONIBACTERIUM ACNES;

ANTIBACTERIAL ACTIVITY; ANTIMYCOBACTERIAL AGENTS; ISOTHIAZOLOPYRIDINE; SYNTHESIS;

ANIMALS; ANTITUBERCULAR AGENTS; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; CRYSTALLOGRAPHY, X-RAY; MICROBIAL SENSITIVITY TESTS; MOLECULAR CONFORMATION; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; PROPIONIBACTERIUM ACNES; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; VERO CELLS;

EID: 84881370658     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2013.06.027     Document Type: Article

References (28)

1. D. Ranft, G. Lehwark-Yvetot, K. Schaper, and A. Buge Arch. Pharm. Pharm. Med. Chem. 330 1997 169
2. A. Carta, G. Paglietti, M. Rahgar Nikookar, P. Sanna, L. Sechi, and S. Zanetti Eur. J. Med. Chem. 37 2002 355
3. T. Renau, J. Sanchez, J. Gage, J. Deyer, M. Shapiro, S. Gracheck, and J. Domagala J. Med. Chem. 39 1996 729
4. G. Pagani, P. Borgna, C. Piersimoni, D. Nista, M. Terreni, and M. Pregnolato Arch. Pharm. Pharm. Med. Chem. 329 1996 421
5. R. Okachi, H. Niino, K. Kitaura, K. Mineura, Y. Nakamizo, Y. Murayama, T. Ono, and A. Nakamizo J. Med. Chem. 28 1985 1772
6. M.A. Ortega, M.E. Montoya, A. Jaso, B. Zarranz, I. Tirapu, I. Aldana, and A. Monge Pharmazie 56 2001 205
7. F. Zani, M. Incerti, R. Ferretti, and P. Vicini Eur. J. Med. Chem. 44 2009 2741
8. W. Hamama, H. Zoorob, M. Gouda, and E. Afsah Pharm. Chem. J. 45 2011 118
9. P. Vicini, A. Geronikaki, M. Incerti, F. Zani, J. Dearden, and M. Hewitt Bioorg. Med. Chem. 16 2008 3714
10. W. Malinka, P. Świa̧tek, B. Filipek, J. Sapa, A. Jezierska, and A. Koll Farmaco 60 2005 961
11. W. Malinka, and M. Rutkowska Farmaco 52 1997 595
12. K. Baggaley, P. English, J. Jennings, B. Morgan, B. Nunn, and W. Tyrrell J. Med. Chem. 28 1985 1661
13. Shroot, B.; Maignan, J. C.A. 103 215278c 1985; C.A. 101 116736c 1984; C.A. 100 121052k 1984.
14. W. Malinka, M. Sieklucka-Dziuba, G. Rajtar, W. Zgodziński, and Z. Kleinrok Pharmazie 55 2000 416
15. W. Malinka, S. Ryng, M. Sieklucka-Dziuba, G. Rajtar, A. Głowniak, and Z. Kleinrok Farmaco 53 1998 504
16. W. Meindl, E. von Angerer, H. Schrönenberg, and G. Ruckdeschel J. Med. Chem. 27 1984 1111
17. W. Malinka Acta Pol. Pharm. - Drug Res. 48 1991 19
18. W. Malinka Acta Pol. Pharm. - Drug Res. 47 1990 51
19. T. Zawisza, and W. Malinka Farmaco 40 1985 124
20. Z. Karczmarzyk, and W. Malinka J. Chem. Crystallogr. 34 2004 453
21. Z. Karczmarzyk, and W. Malinka J. Mol. Struct. 888 2008 160
22. Malinka, W.; Świa̧tek, P.; Ga̧siorowski, K.; Jaszczyszyn, A. Polish Patent No. PL211760, 2012.
23. Bruker. sadabs (Version 2004/1). Bruker AXS Inc.: Madison, Wisconsin, USA, 2005.
24. A. Altomare, G. Cascarano, C. Giacovazzo, and A. Guagliardi J. Appl. Crystallogr. 26 1993 343
25. G.M. Sheldrick Acta Crystallogr. A64 2008 112
26. L.J. Farrugia J. Appl. Crystallogr. 32 1999 837
27. L. Collins, and S.G. Franzblau Antimicrob. Agents Chemother. 1004 1997 41
28. S.A. Ahmed, R.M. Gogal, and J.E. Walsh J. Immunol. Methods 170 1994 211